What is already known about this subject?
Dapagliflozin
is a potent sodium-glucose cotransporter type 2 inhibitor used for the
treatment of type 2 diabetes mellitus (T2DM) worldwide, type 1
diabetes mellitus (T1DM) currently in Europe and Japan, and heart
failure with reduced ejection fraction in USA and Europe.